Sequencing & Diagnostics
16S, shotgun, metatranscriptomics — what each method tells you and what it can't.
What's covered
- 0116S rRNA amplicon sequencing: method, resolution, limitations
- 02Shotgun metagenomics: species/strain resolution, functional prediction
- 03Metatranscriptomics: what's active vs what's present
- 04Metabolomics integration: linking function to composition
- 05Clinical microbiome testing: what's validated vs what's marketed
- 06Batch effects, DNA extraction bias, and reproducibility
By the end of this module you will be able to
- L01Compare 16S amplicon and shotgun metagenomics for resolution, cost, and clinical utility.
- L02Explain why 'who is there' (taxonomy) often matters less than 'what are they doing' (function).
- L03Identify the main sources of technical bias in microbiome studies.
- L04Evaluate the clinical validity of consumer microbiome testing kits.
What you should walk away believing
- →16S gives genus-level taxonomy cheaply; shotgun gives species/strain + function but costs more.
- →Most consumer microbiome tests lack clinical validation — they can tell you composition but not what to do about it.
- →Technical choices (DNA extraction method, sequencing platform, bioinformatics pipeline) can change results more than biology.
What this means for you
Scientists study the microbiome by reading the DNA of all the organisms in a sample. There are different methods — some give broad overviews, others give detailed pictures. Consumer testing kits can tell you what bacteria you have, but they can't reliably tell you what to eat or which supplements to take.
16S rRNA sequencing targets variable regions (V1–V9) and provides genus-level taxonomy at low cost (~$50–150/sample). Shotgun metagenomics sequences all DNA, providing species/strain-level resolution and functional gene prediction but at higher cost (~$200–500). Clinical validity: only specific pathogen detection (e.g., C. diff toxin, GAS) is clinically validated. Broad microbiome profiling lacks actionable reference ranges, and no consumer test is FDA-cleared for diagnostic use.
The MBQC (Microbiome Quality Control Project) demonstrated that DNA extraction method and bioinformatics pipeline introduce more variance than biological differences between individuals. Standardization efforts (IHMS, Earth Microbiome Project protocols) are critical. Long-read sequencing (PacBio, Oxford Nanopore) enables full-length 16S and strain-resolved metagenomics, partially resolving the amplicon-vs-shotgun trade-off.
Interpreting a consumer microbiome report
A 35-year-old brings in a consumer stool microbiome test report showing 'low Akkermansia,' 'high Proteobacteria,' and a 'microbiome health score' of 42/100. The company recommends a $89/month supplement subscription to 'fix' these findings.
How would you interpret this report for the patient, explain the limitations of consumer testing, and advise on whether any action is warranted?
What the data says
Test yourself
Spaced review
Key terms & abbreviations
- 16S rRNA sequencing
- Amplicon-based method targeting the 16S ribosomal RNA gene to identify bacteria at genus level.
- Shotgun metagenomics
- Untargeted sequencing of all DNA in a sample, providing species/strain-level taxonomy and functional gene prediction.
- Metatranscriptomics
- RNA sequencing of microbial communities to determine which genes are actively being expressed.
Optional deeper dive
- Assessment of variation in microbial community amplicon sequencing by the MBQC — Sinha R et al., Nat Biotechnol 2017↗